Payment overview · 2025
General Payments
$674.44
44 reported records · 7 companies
Healthcare provider profile · identity verified
Eric C Heasley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLAIRSVILLE, PA · NPI 1811954837
Verified facts
What the public records show
CMS Open Payments records show Eric C Heasley, MD received $674.44 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 59.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $402.06 | 59.6% | 35 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $197.48 | 29.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.74 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.06 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.33 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.29 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.48 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $674.44 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $361.54 | 31 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $328.44 | 28 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $197.48 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.52 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
103 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1302 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1074 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 1037 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 995 | 155 |
| Lisinopril | Lisinopril | 986 | 148 |
| Pantoprazole Sodium | Pantoprazole Sodium | 796 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 692 | 65 |
| Potassium Chloride | Potassium Chloride | 643 | 63 |
| Furosemide | Furosemide | 525 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 523 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 519 | 56 |
| Metformin Hcl | Metformin Hcl | 516 | 65 |
| Gabapentin | Gabapentin | 499 | 62 |
| Sertraline Hcl | Sertraline Hcl | 474 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 442 | 44 |
| Eliquis | Apixaban | 442 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 424 | 62 |
| Omeprazole | Omeprazole | 422 | 66 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 337 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 49 |
| Trazodone Hcl | Trazodone Hcl | 317 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 310 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 294 | 98 |
| Mirtazapine | Mirtazapine | 291 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 277 | 114 |
| Losartan Potassium | Losartan Potassium | 276 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 48 |
| Simvastatin | Simvastatin | 246 | 41 |
| Tramadol Hcl | Tramadol Hcl | 241 | 85 |
| Metformin Hcl Er | Metformin Hcl | 238 | 43 |
| Celecoxib | Celecoxib | 233 | 28 |
| Famotidine | Famotidine | 227 | 44 |
| Xarelto | Rivaroxaban | 220 | 19 |
| Buspirone Hcl | Buspirone Hcl | 197 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 192 | 30 |
| Allopurinol | Allopurinol | 186 | 27 |
| Meloxicam | Meloxicam | 184 | 57 |
| Jardiance | Empagliflozin | 183 | 43 |
| Azithromycin | Azithromycin | 177 | 91 |
| Paroxetine Hcl | Paroxetine Hcl | 176 | 20 |
| Atenolol | Atenolol | 175 | 20 |
| Donepezil Hcl | Donepezil Hcl | 171 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 70 |
| Glimepiride | Glimepiride | 164 | 32 |
| Pregabalin | Pregabalin | 159 | 26 |
| Montelukast Sodium | Montelukast Sodium | 153 | 16 |
| Myrbetriq | Mirabegron | 150 | suppressed |
| Finasteride | Finasteride | 148 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 146 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 34 |
| Risperidone | Risperidone | 138 | suppressed |
| Bumetanide | Bumetanide | 137 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 14 |
| Meclizine Hcl | Meclizine Hcl | 136 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 135 | 26 |
| Methylprednisolone | Methylprednisolone | 132 | 115 |
| Carvedilol | Carvedilol | 130 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 130 | suppressed |
| Tradjenta | Linagliptin | 127 | 21 |
| Verapamil Er | Verapamil Hcl | 124 | suppressed |
| Alprazolam | Alprazolam | 119 | 26 |
| Bupropion Xl | Bupropion Hcl | 116 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 115 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 114 | 26 |
| Valsartan | Valsartan | 114 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 107 | suppressed |
| Brilinta | Ticagrelor | 103 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 21 |
| Ezetimibe | Ezetimibe | 94 | 19 |
| Lorazepam | Lorazepam | 94 | 33 |
| Ozempic | Semaglutide | 92 | 18 |
| Primidone | Primidone | 91 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 86 | suppressed |
| Aripiprazole | Aripiprazole | 85 | suppressed |
| Lamotrigine | Lamotrigine | 85 | suppressed |
| Baclofen | Baclofen | 84 | suppressed |
| Glipizide | Glipizide | 84 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 77 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | suppressed |
| Memantine Hcl | Memantine Hcl | 77 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 76 | 14 |
| Synthroid | Levothyroxine Sodium | 76 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 14 |
| Spironolactone | Spironolactone | 73 | 12 |
| Topiramate | Topiramate | 73 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 72 | 15 |
| Ursodiol | Ursodiol | 71 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 67 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 67 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | suppressed |
| Colchicine | Colchicine | 65 | suppressed |
| Entresto | Sacubitril/Valsartan | 63 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 36 |
| Clonazepam | Clonazepam | 61 | 20 |
| Trulicity | Dulaglutide | 60 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | suppressed |
| Gemtesa | Vibegron | 58 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 57 | suppressed |
| Methocarbamol | Methocarbamol | 57 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 46 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 55 | suppressed |
| Glyburide | Glyburide | 53 | suppressed |
| Latanoprost | Latanoprost | 53 | suppressed |
| Novolog Flexpen | Insulin Aspart | 53 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | suppressed |
| Sucralfate | Sucralfate | 51 | 11 |
| Anastrozole | Anastrozole | 50 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 50 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Fentanyl | Fentanyl | 45 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 18 |
| Warfarin Sodium | Warfarin Sodium | 44 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 14 |
| Linzess | Linaclotide | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 18 |
| Ondansetron Odt | Ondansetron | 36 | 22 |
| Prednisone | Prednisone | 36 | 23 |
| Lactulose | Lactulose | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 34 | suppressed |
| Oxycontin | Oxycodone Hcl | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 33 |
| Cefdinir | Cefdinir | 33 | 24 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 26 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 16 |
| Mesalamine | Mesalamine | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 12 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 14 |
| Nystatin | Nystatin | 25 | 15 |
| Hydrocortisone | Hydrocortisone | 24 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Roflumilast | Roflumilast | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | 12 |
| Naloxone Hcl | Naloxone Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nifedipine | Nifedipine | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | 15 |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $674.44 · 44 records | ABBVIE INC. | Dexcom G6 Transmitter, FARXIGA, IBSRELA, QULIPTA, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error